Deep inside ovarian theca cells, a protein better known for its role in cellular housekeeping has been implicated in one of the most common endocrine disorders in women of reproductive age. DENND1A¹¹ DENND1A
DENN domain containing 1A; a guanine nucleotide exchange factor for RAB35 involved in clathrin-mediated endocytosis and receptor recycling sits at chromosome 9q33.3, a locus that genome-wide association studies have now replicated across multiple ethnicities as a polycystic ovary syndrome (PCOS) susceptibility region. The rs7852296 variant is an intronic tag SNP within this locus — the A allele marks a haplotype associated with elevated DENND1A expression in the tissues that produce androgens.

The Mechanism

DENND1A generates two splice variants. The canonical transcript (V1) participates in normal endosomal recycling. The shorter splice variant, DENND1A.V2²² DENND1A.V2
the truncated isoform that retains the DENN domain but lacks the long C-terminal tail of V1; overexpressed in PCOS theca cells at both mRNA and protein level, accumulates selectively in PCOS-affected theca cells. When DENND1A.V2 is overexpressed experimentally in normal theca cells, CYP17A1 — the rate-limiting enzyme for androgen synthesis — is markedly upregulated, recapitulating the excess androgen production that characterises PCOS.

A complementary mechanism was identified in granulosa cells. Dou et al. 2024³³ Dou et al. 2024
DENND1A desensitizes granulosa cells to FSH by arresting intracellular FSHR transportation. Sci China Life Sci 67:1587–1600 demonstrated that elevated DENND1A expression disrupts the intracellular trafficking of the follicle-stimulating hormone receptor (FSHR), promoting its internalization while inhibiting recycling back to the cell surface. The net effect is FSH resistance — the granulosa cells cannot mount a normal response to the gonadotropin that drives follicle maturation. Transgenic mice overexpressing DENND1A showed reduced fertility, irregular cycles, and elevated testosterone, mirroring the human PCOS phenotype.

The causal chain from locus to disease was further anchored by a 2025 Nature Communications study: Sankaranarayanan et al. 2025⁴⁴ Sankaranarayanan et al. 2025
Gene regulatory activity associated with PCOS revealed DENND1A-dependent testosterone production. Nat Commun 16:7123 used STARR-seq to map regulatory elements within the DENND1A locus, identifying four variants with allele-specific activity that function as expression QTLs. CRISPR epigenome editing confirmed that activating these regulatory elements raises DENND1A expression and, downstream, testosterone production in adrenal cell models.

The Evidence

The DENND1A locus at 9q33.3 was first identified as a PCOS susceptibility region in Chinese cohorts and subsequently replicated in European populations. Goodarzi et al. 2012⁵⁵ Goodarzi et al. 2012
Replication of association of DENND1A and THADA variants with PCOS in European cohorts. J Med Genet 49:90–95 tested seven SNPs across LHCGR, THADA, and DENND1A in nearly 2,500 European PCOS cases and controls. The rs10818854-A allele showed the strongest DENND1A signal (combined OR 1.87, 95% CI 1.48–2.35, p=9.8×10⁻⁸; BMI-adjusted OR 2.02, p=6.5×10⁻⁸). The same paper noted that rs7852296, a neighbouring intronic variant in the same gene, had been associated with the personality dimension of Persistence in a genome-wide scan (p=9×10⁻⁶), illustrating that DENND1A regulatory variation influences diverse phenotypes across tissues.

A large European meta-analysis — Day et al. 2018⁶⁶ Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813 — combining 10,074 PCOS cases and 103,164 controls confirmed DENND1A as one of 14 replicated PCOS loci (rs9696009-A, beta 0.20, p=10⁻¹¹). Evidence that rare DENND1A noncoding variants contribute beyond common SNPs comes from whole-genome sequencing of PCOS families: Dapas et al. 2020⁷⁷ Dapas et al. 2020
Distinct subtypes of PCOS with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med 17:e1003043 showed that carriers of rare DENND1A deleterious variants were significantly enriched in the reproductive PCOS subtype (high LH, normal BMI), underscoring that the locus exerts its effect primarily through the reproductive axis rather than the metabolic one.

The variant-level evidence for rs7852296 itself is sub-genome-wide-significant for PCOS (it appears in the GWAS Catalog as a DENND1A association with beta 0.17). Its clinical utility derives from its position as a tag SNP marking the broader DENND1A susceptibility haplotype, which has been replicated at genome-wide significance in multiple independent cohorts.

Practical Actions

Because the DENND1A mechanism is reproductive rather than metabolic, monitoring is most valuable in women with clinical signs of PCOS — irregular cycles, acne, excess hair growth, or difficulty conceiving. Elevated androgen levels (free testosterone, DHEAS) are the biomarker most directly connected to DENND1A pathway activity. Anti-Müllerian hormone (AMH) reflects the follicular arrest that FSH resistance produces, and elevated AMH is a hallmark of the reproductive PCOS subtype enriched for DENND1A variants.

Inositol supplementation — specifically myo-inositol and D-chiro-inositol — acts downstream of FSH signalling to improve ovarian sensitivity and has specific evidence in PCOS with FSH resistance. Spearmint tea has documented anti-androgenic activity in PCOS (reduces free testosterone via LH/FSH modulation) without systemic anti-androgen side effects.

Metformin and GLP-1 receptor agonists address the metabolic PCOS phenotype more than the reproductive one and are therefore less specifically targeted to the DENND1A pathway.

Interactions

The strongest known gene-gene interaction at the PCOS susceptibility level involves DENND1A together with THADA (rs13429458) and LHCGR (rs13405728). Each locus contributes independently to PCOS risk in European cohorts (Goodarzi 2012). Individuals carrying risk alleles at all three loci would represent the highest polygenic burden from this trio of loci, but no published compound effect size exists for the triple combination.

The reproductive PCOS subtype (enriched for DENND1A variants) overlaps with elevated LH pulsatility — making GNRH/LH axis variants (LHCGR rs13405728) the most biologically coherent interaction partner. The combined effect of impaired FSHR recycling (DENND1A) and altered LH receptor signalling (LHCGR) on follicular dynamics warrants investigation as a compound interaction.

Beneath the surface of allergic asthma, rhinitis, and eczema lies a shared distress signal: IL-33¹¹ IL-33
Interleukin-33, an alarmin cytokine stored in the nuclei of epithelial cells lining the airways, gut, and skin; released upon cell damage or allergen exposure, it binds the ST2 (IL1RL1) receptor on mast cells, ILC2 innate lymphoid cells, and eosinophils to initiate type-2 inflammation. rs1342326 sits approximately 25 kilobases upstream of the IL33 transcription start site on chromosome 9. The C allele acts as a gain-of-expression variant: carriers produce more IL-33 mRNA in bronchial epithelium, meaning every allergen challenge, viral rhinitis, or pollutant exposure generates a louder alarm. The GABRIEL consortium's genome-wide association study²² GABRIEL consortium's genome-wide association study
Moffatt et al. 2010, N=26,475; p=9×10⁻¹⁰ first established this SNP at genome-wide significance for asthma risk, and it has since been replicated across multiple European, Middle Eastern, and pediatric cohorts for asthma, allergic rhinitis, and hay fever.

The Mechanism

rs1342326 is a regulatory (eQTL) variant³³ regulatory (eQTL) variant
Expression quantitative trait locus — a variant that influences how much RNA is made from a nearby gene, without changing the protein sequence in the IL33 upstream regulatory region. The C allele is associated with measurably higher serum IL-33 protein concentrations in carriers, confirmed in the Tunisian pediatric cohort (Charrad et al. 2018)⁴⁴ (Charrad et al. 2018)
PMID 28985997. Higher constitutive IL-33 output means that the ST2/IL1RL1 receptor system — which mediates type-2 immune activation on mast cells, ILC2s, and eosinophils — is chronically primed above population baseline.

A second immune mechanism emerges from the PASTURE/EFRAIM birth cohort: C allele carriers show significantly reduced regulatory T cells (Tregs)⁵⁵ regulatory T cells (Tregs)
CD4+CD25+FOXP3+ cells that suppress immune overactivation; lower Treg frequency is associated with impaired allergen tolerance and higher atopic disease risk and elevated SOCS3 mRNA expression, which negatively correlates with Treg abundance (Schröder et al. 2016). This suggests that the rs1342326-C allele not only increases IL-33 output but also undermines the immune regulatory circuitry that normally limits Th2 responses — a compounding effect that helps explain the variant's association with multiple atopic phenotypes simultaneously.

The Evidence

The landmark GABRIEL GWAS⁶⁶ GABRIEL GWAS
Moffatt et al. NEJM 2010; 10,365 cases + 16,110 controls from European populations; genome-wide significance p=9×10⁻¹⁰ placed rs1342326 at the IL33 locus as one of the reproducible asthma risk signals, alongside IL1RL1 (ST2 receptor), HLA-DQ, and ORMDL3/GSDMB. The C allele risk allele frequency of ~16% in Europeans means a substantial fraction of the population carries at least one copy.

Pediatric longitudinal data strengthens the causal interpretation. In the Finnish post-bronchiolitis cohort⁷⁷ post-bronchiolitis cohort
Korppi et al. Acta Paediatr 2020; 141 children followed to ages 6 and 12, AC/CC carriers showed OR 2.17 for allergic rhinitis at age 6.4, rising to OR 3.23 at age 11.7 — a signal that strengthens over time, consistent with the progressive nature of atopic march. Notably, 22.5% of variant carriers required inhaled corticosteroids by age 6 versus only 8.9% of AA homozygotes.

In an Iranian adult case-control study (Matloubi et al. 2020⁸⁸ (Matloubi et al. 2020
126 asthmatics + 300 controls), the CC genotype carried OR 2.50 (95% CI 1.33–4.69) for asthma and was specifically associated with the atopic, eosinophil-elevated subtype. The elevated peripheral eosinophil counts in CC carriers confirm that the IL33-C eQTL effect flows through the IL-33→ST2→eosinophil axis, producing the quantitative biomarker signature consistent with type-2 high asthma.

An important pharmacogenomic signal comes from a Canadian pediatric exacerbation study⁹⁹ Canadian pediatric exacerbation study
Tse et al. Pediatr Pulmonol 2019; 491 children with acute moderate-to-severe asthma exacerbations: C allele carriers experienced significantly worse acute outcomes (management failure OR 0.52 for AA vs other genotypes), with higher rates of hospitalization and prolonged emergency care — suggesting that elevated IL-33 signaling during acute viral triggers drives more severe exacerbation phenotypes that are harder to control acutely.

Practical Implications

The C allele's mechanism — elevated IL-33 output → chronically primed ST2/eosinophil axis — points to two monitoring priorities: (1) tracking the downstream eosinophil and airway inflammation burden with FeNO and blood eosinophil count, and (2) being alert to the atopic march trajectory, particularly after early-life respiratory infections. IL-33 itself is now a pharmaceutical target: itepekimab (Dupixent's companion anti-IL-33 antibody) and tezepelumab (anti-TSLP, which synergises with IL-33 upstream) both mechanistically converge on the pathway amplified by this variant. Carriers with moderate-to-severe asthma are biologically well-matched to biologics that interrupt upstream type-2 signaling.

Interactions

rs1342326 (IL33 ligand, elevated expression) and rs1420101 (IL1RL1/ST2 receptor, reduced sST2 decoy expression) represent two nodes of the same IL-33 signaling axis. The rs1420101-T allele lowers circulating soluble ST2 — the natural IL-33 decoy receptor — so IL-33 is less buffered. Carrying C at rs1342326 and T at rs1420101 compounds both ends: more IL-33 released AND less decoy to intercept it. This interaction is documented in the literature on the IL-33/ST2 pathway and is captured in compound actions in this database. The related IL33 variant rs992969 tags a second upstream regulatory position also associated with increased IL33 expression; compound carriers of both IL33 risk alleles carry additive expression burden.

Clusterin (CLU), also known as apolipoprotein J, is the third strongest known genetic risk factor for late-onset Alzheimer's disease after APOE and BIN1. It is a secreted molecular chaperone that binds misfolded proteins — including amyloid-beta (Aβ) — and escorts them out of the brain across the blood-brain barrier. The rs1532278 variant sits in an intronic regulatory region of the CLU gene and is one of the most studied and most robustly replicated Alzheimer's risk loci in the entire human genome.

The Mechanism

CLU exerts its neuroprotective effect through two overlapping pathways. First, secreted clusterin forms stable complexes with Aβ and facilitates its clearance from the brain across the blood-brain barrier¹¹ blood-brain barrier
the highly selective barrier between brain tissue and circulating blood via the LRP2 receptor. Second, CLU inhibits Aβ oligomerization and aggregation directly, preventing the formation of the toxic soluble oligomers that damage synapses before plaques ever appear.

Rs1532278 is located in an intronic open chromatin region — a regulatory element — in glutamatergic (excitatory) neurons. A 2025 study using CRISPR editing of human iPSC-derived neurons showed that only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons²² only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons
Zhao et al., Molecular Neurodegeneration, 2025. The T allele creates stronger binding for the ISL2 transcription factor, retaining approximately 80% more binding capacity than the C allele. This drives elevated neuronal CLU transcription and secretion.

The protective T allele's downstream effect is measurable: T/T carriers show approximately 40–50% higher CLU mRNA expression in glutamatergic neurons compared to C/C carriers, along with greater dendritic complexity, enhanced synaptic marker expression, and higher neuronal firing frequency. Elevated neuronal CLU promotes neuron-to-astrocyte lipid transfer, increasing astrocytic lipid droplet accumulation and fine-tuning glutamate clearance — a lipid-mediated neuron-glia communication pathway that supports neuronal resilience.

The Evidence

CLU was first identified as an Alzheimer's risk locus in the landmark 2009 Harold et al. GWAS³³ 2009 Harold et al. GWAS
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009 (5,964 cases + controls, OR = 0.86 for the protective haplotype). Rs1532278 is in near-complete linkage disequilibrium with rs11136000 (r² = 0.95, D′ = 0.99), the originally reported CLU lead SNP — but rs1532278 shows slightly stronger association with ventricular expansion and Aβ deposition, suggesting it sits closer to the true causal variant.

A 2010 meta-analysis confirmed the CLU association across 15,000+ individuals⁴⁴ confirmed the CLU association across 15,000+ individuals
Jun et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci. Archives of Neurology, 2010 (OR = 0.91, 95% CI 0.85–0.96), and showed the CLU effect is independent of APOE ε4 status — unlike PICALM, whose effect is largely confined to ε4 carriers. The 2025 functional study reported an even more significant signal at rs1532278 specifically: OR = 0.905 with p = 3.2 × 10⁻³³ in a large meta-GWAS.

Plasma clusterin levels serve as a biomarker for AD progression. Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6⁵⁵ Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6
Jongbloed et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. J Alzheimers Dis, 2015 and correlated with faster cognitive decline (r = −0.38). Notably, C/C homozygotes have higher plasma clusterin concentrations, reflecting a compensatory upregulation in response to reduced brain clearance efficiency.

Practical Actions

Rs1532278 C/C and C/T carriers do not have a pathogenic variant — this is a common risk-modifying SNP, not a disease-causing mutation. The C allele is carried by approximately 86% of people in some form (C/C or C/T). Practical focus for C-allele carriers is on lifestyle factors that support the CLU-Aβ clearance pathway: omega-3 fatty acids support neuronal membrane integrity and reduce neuroinflammation at CLU-relevant pathway nodes; aerobic exercise increases CLU expression in hippocampal tissue; and avoiding chronic sleep deprivation is specifically relevant because Aβ clearance via the glymphatic system is maximally active during deep sleep — a pathway that overlaps functionally with CLU-mediated BBB clearance.

Monitoring cognition from midlife is meaningful for C/C homozygotes: baseline cognitive assessments with standardized tools (MoCA or MMSE) in the 40s–50s provide early-change detection before symptoms are clinically apparent.

Interactions

The strongest known interaction is with APOE. APOE ε4 and CLU risk alleles both impair Aβ clearance through related but distinct mechanisms — APOE via direct Aβ binding competition and receptor-mediated clearance at LRP1, CLU via LRP2 — and carriers of both risk alleles show amplified ventricular expansion rates and accelerated Aβ accumulation in imaging studies. This CLU × APOE interaction is documented in the literature and is a strong candidate for a compound action (see interaction candidates below).

The CLU locus also contains rs9331888 (exon 1) and rs7982 (exon 5), which affect alternative splicing of CLU transcripts in a sex-dependent manner. These three variants are in partial LD and tag different functional effects within the same gene — rs1532278 affects transcription in neurons, rs9331888 affects splicing, and rs7982 affects intron retention primarily in females.

Deep inside chromosome 9 lies a short stretch of DNA — the 9p21.3 locus — that carries some of the most replicated disease associations ever discovered. Within this region sits ANRIL (antisense non-coding RNA in the INK4 locus), a long non-coding RNA that acts as a molecular volume knob for cellular senescence. Variants in ANRIL are associated, in the same region of the genome, with coronary artery disease, myocardial infarction, type 2 diabetes, intracranial aneurysm, glioma, and physical aging — a concentration of GWAS hits rare in the human genome¹¹ a concentration of GWAS hits rare in the human genome
Pasmant E et al. ANRIL, a long noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011..

rs1537373 is an intronic variant within the ANRIL gene itself (CDKN2B-AS1), positioned at chromosome 9, base 22,103,342 on the GRCh38 reference. It is one of several independent tag SNPs at this locus, each capturing a partially distinct signal. The T allele at rs1537373 is the risk allele for myocardial infarction and brain aneurysm, while the locus as a whole — through nearby variants in strong linkage disequilibrium — also confers type 2 diabetes susceptibility.

The Mechanism

ANRIL is transcribed antisense to three protein-coding genes packed tightly together at 9p21.3: CDKN2B (encoding p15INK4b), CDKN2A (encoding p16INK4a and p14ARF), and MTAP. p15 and p16 are cyclin-dependent kinase inhibitors²² cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4 and CDK6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence. As cells accumulate damage or age, rising p16 and p15 levels lock them in a permanent growth arrest — senescent "zombie" cells³³ senescent "zombie" cells
Senescent cells remain metabolically active but stop dividing, secreting pro-inflammatory cytokines (the SASP) that progressively damage surrounding tissue that fuel atherosclerosis and impair tissue regeneration.

ANRIL regulates CDKN2A/CDKN2B expression in cis by recruiting PRC2 (Polycomb Repressive Complex 2)⁴⁴ PRC2 (Polycomb Repressive Complex 2)
PRC2 deposits repressive H3K27me3 histone marks that silence nearby genes; loss of PRC2 recruitment allows CDKN2A/2B to be more highly expressed, accelerating senescence to silence the INK4 locus. Variants at rs1537373 alter the expression of specific ANRIL isoforms, shifting the balance toward either more or less CDKN2A/2B expression in vascular and pancreatic tissues. In vascular smooth muscle cells (VSMCs), elevated p16/p15 accelerates VSMC senescence and plaque-forming behavior, driving atherosclerosis. In pancreatic beta cells, the same pathway reduces proliferative capacity and total beta-cell mass over decades, impairing insulin production.

Notably, the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping⁵⁵ the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping
Kong et al. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. Front Endocrinol. 2018. PMID:30087655, suggesting distinct ANRIL isoforms and regulatory elements govern each disease phenotype — with rs1537373 primarily tagging the cardiovascular signal at this multi-trait locus.

The Evidence

The 9p21 locus entered the cardiovascular genetics literature with force in 2007. Helgadottir et al.⁶⁶ Helgadottir et al.
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007. PMID:17478679 showed that approximately 21% of the population is homozygous for the risk variant at 9p21, and their estimated MI risk is 1.64 times that of noncarriers — rising to 2.02-fold for early-onset MI. The population attributable risk from this single locus was estimated at 21% for general MI and 31% for early-onset disease.

At the same time, Samani et al. 2007⁷⁷ Samani et al. 2007
Genomewide association analysis of coronary artery disease. NEJM 2007. PMID:17634449 confirmed the 9p21 region (lead SNP rs1333049, in strong LD with rs1537373) as the single strongest genetic risk locus for coronary artery disease ever identified, with a per-allele OR of 1.36 (95% CI 1.27–1.46). These findings have been replicated consistently across dozens of independent cohorts.

GWAS Catalog data specific to rs1537373 shows genome-wide significant associations with myocardial infarction (p = 2×10⁻⁷¹), brain aneurysm (p = 3×10⁻²² to 3×10⁻²⁹), coronary artery calcification (p = 4×10⁻¹¹), heart failure (p = 2×10⁻¹²), and LDL cholesterol elevation (p = 5×10⁻¹⁷).

The T2D connection at this locus was established by three concurrent 2007 GWAS that identified nearby 9p21 variants (rs10811661, rs564398) as independent T2D susceptibility signals. A meta-analysis by Cugino et al.⁸⁸ meta-analysis by Cugino et al.
Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis 2012. PMID:21315566 across 22 studies (38,455 T2D cases, 60,516 controls) confirmed per-allele OR 1.24 (P < 10⁻¹⁵) for the primary 9p21 T2D signal, with 15% population attributable risk in Caucasians.

Practical Actions

The GWAS catalog T-allele associations for rs1537373 cover both acute cardiovascular events (MI, aneurysm) and metabolic disease (T2D, LDL). Actions at this locus target:

• Reducing atherosclerotic plaque progression through dietary and monitoring strategies
• Catching asymptomatic coronary artery disease early, when intervention is most effective
• Managing the metabolic stressors that exhaust beta-cell reserves

A critical finding: Do et al. 2012⁹⁹ Do et al. 2012
INTERHEART and FINRISK study of diet-gene interaction at 9p21. PMID:22022235 showed that among those with the highest "prudent diet" scores (rich in raw vegetables and fruits), the 9p21 genetic risk for MI was effectively abolished. Among those with low prudent diet scores and two risk alleles, MI risk was doubled. The dietary interaction at this locus is one of the strongest gene-diet interactions in cardiovascular genetics.

Interactions

rs1537373 is in strong linkage disequilibrium with the primary CAD variant rs1333049 and with the T2D variants rs10811661 and rs564398 — all within the same ~200 kb stretch of 9p21.3. These variants together capture overlapping but distinct regulatory signals within the ANRIL locus. Carrying risk alleles at multiple 9p21 positions compounds risk across cardiovascular and metabolic phenotypes through shared cellular senescence biology.

The longevity-associated rs2811712 within ANRIL (covered in the Longevity & Aging category) represents a further independent signal at the same gene, primarily associated with age-related physical function and frailty — illustrating how different ANRIL isoforms modulate distinct tissue-specific aspects of aging.

Methionine synthase reductase (MTRR) maintains the one-carbon methylation cycle by reactivating methionine synthase (MTR) after its methylcobalamin cofactor becomes oxidized during catalysis. When MTRR function is impaired — whether by coding variants that reduce enzyme efficiency or by regulatory variants that reduce enzyme expression — homocysteine accumulates and global DNA methylation declines, processes linked to genomic instability and tumor suppressor silencing.

rs162040 is an intronic variant at chromosome 5 position 7,887,365 (GRCh38), within an MTRR haplotype block also containing rs3776467, rs326124, and rs3776455. The GRCh38 reference allele at this position is C, but C is the population minority (~11% globally in gnomAD v4, ~31% in East Asian populations). The common A allele (~89% globally) represents the baseline protective state; the C allele marks the risk haplotype.

The Mechanism

As an intronic variant, rs162040 does not alter the MTRR protein sequence. Its biological significance lies in its membership in a functional MTRR regulatory haplotype. The parallel between rs162040 and the neighboring intronic variants rs3776467 and rs326124 — all showing the same alcohol-modulated survival signal in the same dataset — suggests they tag a shared regulatory element or splice-regulatory sequence within MTRR introns. Such elements can influence MTRR transcript levels or alternative splicing¹¹ MTRR transcript levels or alternative splicing
Intronic regulatory elements including branch point sequences, exonic splicing enhancers, and lncRNA binding sites can alter gene expression without changing the protein coding sequence. Reduced MTRR expression would impair B12 reactivation, slowing MTR-catalyzed homocysteine remethylation and depleting SAM (the universal methyl donor) — the same downstream consequence as coding impairments.

The Evidence

The primary evidence comes from the Newfoundland Familial Colorectal Cancer Study²² Newfoundland Familial Colorectal Cancer Study
Wang Y et al. The Roles of MTRR and MTHFR Gene Polymorphisms in Colorectal Cancer Survival. Nutrients, 2022, which followed 532 patients with newly diagnosed colorectal cancer (1999–2003) through April 2010. The study genotyped 33 MTRR and MTHFR tag SNPs and assessed their association with overall survival (OS) and disease-free survival (DFS).

For rs162040, as part of the MTRR haplotype block, a significant interaction was found with pre-diagnostic alcohol consumption: protective A-allele carriers showed superior overall survival, but this benefit was restricted to patients consuming alcohol below the cohort median of 2.17 g/day (roughly one standard drink per week). Among patients with higher alcohol intake, the allele-associated survival difference was abolished. This interaction pattern — replicated across rs162040, rs3776467, rs326124, and rs3776455 in the same analysis — is consistent with alcohol's known disruption of folate absorption and one-carbon methyl-donor homeostasis. Alcohol depletes intestinal folate uptake and increases urinary folate excretion, amplifying any underlying impairment of MTRR-dependent B12 recycling.

The evidence base is limited: one survival cohort study in CRC patients, with rs162040 analyzed as part of a haplotype block rather than as an isolated variant. No population-based homocysteine data, no in vitro MTRR expression studies, and no prospective healthy-population data exist for rs162040 specifically. Evidence level is emerging.

Practical Actions

For C-allele carriers, two modifiable factors interact with the rs162040 haplotype: alcohol intake and B12/folate status. Keeping alcohol intake consistently low removes the primary amplifying factor for MTRR-related methylation disruption. Using active B12 forms (methylcobalamin or hydroxocobalamin rather than cyanocobalamin) and methylfolate instead of synthetic folic acid supports the one-carbon cycle even when MTRR regulatory capacity is reduced.

Monitoring plasma homocysteine provides an objective readout of functional methylation status. Elevated homocysteine (above 10 µmol/L) with normal dietary B12 intake signals that recycling pathway demand exceeds capacity and warrants targeted supplementation.

Interactions

rs162040 sits in the same MTRR intronic haplotype block as rs3776467, rs326124, and rs3776455, all of which showed parallel alcohol-survival interactions in the Wang 2022 cohort. The coding variant rs1801394 (MTRR A66G, p.Ile22Met), which reduces MTRR catalytic efficiency, operates through a complementary mechanism — carriers of both the regulatory risk haplotype (rs162040 C allele) and the coding impairment (rs1801394 G allele) may face compounded MTRR dysfunction. Upstream impairments in MTHFR (rs1801133 C677T, reduced methylfolate production) or MTR (rs1805087 A2756G, reduced methionine synthase activity) further amplify the downstream consequences of impaired MTRR B12 recycling.

Brown adipose tissue (BAT) is the body's built-in furnace. Unlike white fat, which stores energy, brown fat burns calories by uncoupling the mitochondrial electron transport chain from ATP synthesis — dissipating energy directly as heat. The master switch for this process is uncoupling protein 1 (UCP1), encoded by the UCP1 gene on chromosome 4q31. The A-3826G polymorphism (rs1800592) sits in the promoter region, approximately 3,826 base pairs upstream of the UCP1 transcription start site, where it directly influences how much UCP1 the body can produce.

The Mechanism

UCP1 is on the minus (reverse) strand of chromosome 4. In the standard literature notation, the variant is described as A→G at position -3826; on the plus strand that 23andMe reports, the protective "A" allele appears as T and the risk "G" allele appears as C. This regulatory SNP¹¹ regulatory SNP
A single-nucleotide change in non-coding DNA that alters gene expression rather than protein structure lies within a complex enhancer region (positions -3820 to -3470) containing multiple cis-acting elements, including a putative retinoic acid response element and an ATF/CREB-like binding site. Transfection experiments demonstrate that the haplotype containing the protective A allele (T on plus strand) drives significantly higher luciferase reporter activity than the G-risk haplotype (C on plus strand), with the GG haplotype showing virtually no basal transcriptional activity. In obese individuals, G-allele carriers have measurably reduced UCP1 mRNA expression²² reduced UCP1 mRNA expression
Confirmed in adipose tissue biopsies; the G allele impairs promoter activity and downstream thermogenic signaling, translating the promoter SNP directly into reduced thermogenic protein abundance.

The Evidence

The functional consequences appear across multiple physiological contexts. In the earliest human study, Ridderstrale et al. (2003)³³ Ridderstrale et al. (2003)
88 healthy boys aged 8-11; indirect calorimetry after high-fat and high-carbohydrate test meals; JCEM 88(12):5661 showed that after a high-fat meal, GG boys had a significantly lower thermic effect of the meal than AA+AG boys, despite identical sympathetic nervous system activation — the signal to burn calories via UCP1 was present but the thermogenic machinery was impaired.

At rest, the deficit is also measurable. Nagai et al. (2011)⁴⁴ Nagai et al. (2011)
82 healthy young females aged 20-22; indirect calorimetry; International Journal of Obesity 35:1038 found resting energy expenditure was 14% higher in AA women than GG women (5,599 vs 4,919 kJ/day, p<0.01), with AG women intermediate (5,054 kJ/day). Thermoregulatory sympathetic nervous system activity (measured by heart rate variability spectral analysis) was similarly lowest in GG subjects.

Cold exposure reveals the deficit most starkly. Kooijman et al. (2014)⁵⁵ Kooijman et al. (2014)
19 healthy children; acute cold exposure; Pediatric Research 75:227 showed GG children produced less heat when cold-challenged, despite mounting a stronger hormonal stress response (elevated cortisol and autonomic activation) — a costly compensatory effort that failed to fully bridge the thermogenic gap. A 2017 mechanistic study in 47 Japanese males confirmed that AA homozygotes show significantly greater oxygen consumption during cold exposure⁶⁶ AA homozygotes show significantly greater oxygen consumption during cold exposure
VO2 increase p=2.4×10⁻³ to 8.1×10⁻³ across comparison timepoints than heterozygotes or CC carriers.

Long-term consequences emerge through two pathways. First, BAT naturally declines with age, and Yoneshiro et al. (2012)⁷⁷ Yoneshiro et al. (2012)
199 volunteers aged 20-72; FDG-PET/CT after cold exposure; International Journal of Obesity 37:96 found that the G allele (plus-strand C) significantly accelerates this decline: in older subjects, GG individuals had 0% BAT detection rate vs 24% in A-allele carriers (p<0.05), with correspondingly higher visceral fat. Second, brown fat's impact is strongly seasonal: Yoneshiro et al. (2013)⁸⁸ Yoneshiro et al. (2013)
3,013 Japanese adults; seasonal sampling across entire year; PLOS ONE 8:e74720 showed UCP1 genotype predicted visceral fat area specifically during winter months (when BAT is most active), with effects tightly correlated with ambient outdoor temperature (p=0.00011). A Saudi case-control study Al-Daghri et al. (2018)⁹⁹ Al-Daghri et al. (2018)
337 obese vs 155 controls; adjusted OR; BMC Medical Genetics reported OR 1.52 (95% CI 1.10-2.08, p=0.009) for obesity in G-allele carriers. Meta-analyses examining BMI as a continuous outcome have been mixed, likely because the effect is strongest under cold stress rather than in thermoneutral laboratory conditions.

Practical Implications

For CC carriers (GG in traditional notation), the thermogenic gap is present under all conditions — at rest, after high-fat meals, and during cold exposure — but is most physiologically significant in cold environments and as age reduces BAT reserve. Interventions that activate brown fat through alternative pathways can partly compensate. Cold exposure directly stimulates BAT; even mild cool environments (17-19°C) trigger adrenergic BAT activation independent of UCP1 promoter activity. Capsinoids (non-pungent capsaicin analogs found in sweet peppers) activate BAT via the TRPV1 receptor–sympathetic nervous system axis, increasing resting energy expenditure in individuals with active BAT. High-fat meals elicit less diet-induced thermogenesis in GG carriers, making meal composition relevant; carbohydrate-containing meals appear to trigger more UCP1-independent thermogenic pathways.

Interactions

The most documented interaction is with ADRB3 rs4994 (Trp64Arg, β3-adrenergic receptor), which modulates catecholamine-driven BAT activation. Yoneshiro et al. (2012)¹⁰¹⁰ Yoneshiro et al. (2012) showed that the combination of UCP1 G allele and ADRB3 Trp64Arg significantly accelerates age-related BAT decline more than either allele alone. In older adults carrying both risk variants, BAT detection rates were effectively zero and visceral fat accumulation was highest. A Brazilian study found the combined presence of three or more risk alleles across ADRB3 Trp64Arg and UCP1 -3826A/G correlated with protection against overweight when the protective alleles were present (OR=0.288 for overweight with at least three minor alleles). If you also carry the ADRB3 Trp64Arg variant (rs4994), the combined impairment in adrenergic BAT stimulation and UCP1 expression warrants more aggressive cold-exposure and lifestyle strategies than for UCP1 alone.

CYP2C8 is one of the liver's key drug-metabolizing enzymes, responsible for breaking down a broad range of therapeutics including paclitaxel (a widely used chemotherapy agent), thiazolidinedione diabetes drugs, and antimalarials. Beyond drug metabolism, CYP2C8 converts arachidonic acid into epoxyeicosatrienoic acids ¹¹ EETs: lipid mediators with vasodilatory and anti-inflammatory properties, meaning it plays a role in vascular regulation and inflammation even in people who never take any of its substrate drugs.

rs1934951 is an intronic variant²² Intronic: located within a non-coding region between two exons of the CYP2C8 gene in CYP2C8 that has attracted attention primarily in two clinical contexts: bisphosphonate-related osteonecrosis of the jaw (MRONJ) in cancer patients, and taxane-induced peripheral toxicity in chemotherapy recipients.

The Mechanism

The rs1934951 T allele (reported as the A allele in papers using the coding strand, since CYP2C8 is on the minus strand of chromosome 10) falls within intron 9 of CYP2C8 at position c.1291+106. As an intronic variant with no direct protein-coding effect, its functional mechanism is not fully established. It may act as a tag for CYP2C8 haplotype C (HapC), which is associated with altered enzyme activity and expression. CYP2C8 haplotypes differ in their efficiency of substrate metabolism; carriers of HapC may have modified clearance of paclitaxel and potentially altered EET production from arachidonic acid. Bisphosphonates are not CYP2C8 substrates per se, but CYP2C8-driven EET signaling influences osteoclast³³ Osteoclasts: bone-resorbing cells regulated in part by EET lipid mediators activity and bone microvasculature, providing a plausible biological link.

The Evidence

The original finding came from a genome-wide association study in multiple myeloma patients⁴⁴ genome-wide association study in multiple myeloma patients
Sarasquete ME et al. Bisphosphonate-related osteonecrosis of the jaw associated with CYP2C8 polymorphisms. Blood, 2008 receiving bisphosphonates. In 22 cases of jaw osteonecrosis versus 65 matched controls, the T allele (papers call it A) was dramatically overrepresented in cases (48% vs 12%), with homozygous TT carriers at 12.75-fold increased risk (OR 12.75, 95% CI 3.7–43.5, p-corrected = 0.02). A meta-analysis by Zhong et al. (2013)⁵⁵ Zhong et al. (2013)
Zhong DN et al. CYP2C8 rs1934951 polymorphism meta-analysis. Acta Haematol, 2013 found the association held specifically in multiple myeloma patients (dominant model OR 5.77, p=0.028) but not across other cancer types.

However, a comprehensive review by Yang et al. (2019)⁶⁶ Yang et al. (2019)
Yang G et al. Pharmacogenomics of osteonecrosis of the jaw. Bone, 2019 concluded that all six subsequent candidate-gene replication studies failed to confirm this association, attributing the original signal to the small sample size of the discovery GWAS. The MRONJ association must therefore be treated as an initial discovery finding that has not been independently validated.

The chemotherapy toxicity evidence is more consistent. A study of 113 breast cancer patients found rs1934951 significantly associated with paclitaxel-induced anemia (p≤0.01), in conjunction with CYP2C8 haplotype C Boso et al. 2014⁷⁷ Boso et al. 2014
Bosó V et al. SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics, 2014. A more recent multicenter cohort study of 130 ovarian cancer survivors (median 63-month follow-up after chemotherapy) found that T-allele carriers had approximately 2.5-fold increased odds of experiencing severe long-term chemotherapy-induced peripheral neuropathy (OR 2.482, 95% CI 1.13–5.47, p=0.024) Zenatri et al. 2024⁸⁸ Zenatri et al. 2024
Zenatri M et al. Pharmacogenomic predictor of long-term residual CIPN in ovarian cancer survivors. Gynecol Oncol, 2024.

Practical Actions

For individuals who may receive or are considering paclitaxel-based chemotherapy (used in breast, ovarian, lung, and other cancers), T-allele carriers — especially TT homozygotes — should discuss their genotype with their oncologist. Preventive neuropathy management strategies (such as dose modification, cold-cap gloves during infusion, and early physical therapy) are most effective when implemented proactively. For those receiving bisphosphonates (zoledronic acid, pamidronate) for bone protection or myeloma treatment, the MRONJ association remains biologically plausible but replication data is inconsistent; basic dental hygiene protocols before starting bisphosphonate therapy are standard of care for all patients regardless of genotype.

Interactions

rs1934951 may act as a tag for the CYP2C8 haplotype C (HapC), which is defined by a combination of variants including rs10509681 and rs11572080 — other intronic CYP2C8 SNPs also studied in the context of taxane-induced neuropathy. In pharmacogenomics studies, the haplotype may confer stronger predictive value than any single variant alone. The interaction between CYP2C8 metabolizer status and paclitaxel dose intensity has not yet been formalized into CPIC or DPWG guidelines, but multiple independent signals in the same gene strengthen the biological rationale.

The thyroid-stimulating hormone receptor (TSHR) sits on the surface of thyroid follicular cells, where it binds TSH from the pituitary and triggers the production of thyroid hormones T4 and T3. This receptor is a G-protein-coupled receptor¹¹ This receptor is a G-protein-coupled receptor
Activates both cAMP and phospholipase C pathways that controls virtually all aspects of thyroid function — hormone synthesis, thyroid cell growth, and iodine uptake. The Asp727Glu variant changes an aspartic acid to glutamic acid at position 727 in the intracellular tail of the receptor, altering its binding affinity to cyclic AMP²² altering its binding affinity to cyclic AMP
Computational modeling shows distinct binding energies: -7.27 vs -7.34 kcal/mol and thereby modulating signal transduction efficiency. This common polymorphism affects approximately 8-12% of people across populations³³ 8-12% of people across populations
Present in 0.6% as GG homozygotes in European populations and has emerged as a genetic factor influencing TSH levels, metabolic health, and thyroid disease risk.

The Mechanism

The wild-type Asp727 version of the TSHR maintains optimal signal transduction when TSH binds. The variant Glu727 substitution is conservative⁴⁴ The variant Glu727 substitution is conservative
Both aspartic acid and glutamic acid are negatively charged, but the single-carbon side chain difference alters the receptor's interaction with downstream signaling molecules, particularly cyclic AMP. When TSH binds to the receptor's extracellular domain, it triggers a conformational change that activates G proteins⁵⁵ it triggers a conformational change that activates G proteins
Gs protein activates adenylyl cyclase, producing cAMP on the intracellular side. The Glu727 variant appears to enhance this cAMP-mediated signaling pathway, making the receptor slightly more responsive to TSH stimulation. This increased sensitivity means that carriers require less circulating TSH⁶⁶ carriers require less circulating TSH
12.6% lower TSH levels in Glu727 carriers to achieve the same thyroid hormone output, effectively resetting the hypothalamic-pituitary-thyroid axis setpoint.

However, this enhanced receptor sensitivity has a paradoxical effect: in the developing thyroid gland, where proper TSH signaling is critical for differentiation and growth, the altered cAMP dynamics may impair normal thyroid development⁷⁷ impair normal thyroid development
Associated with 2.3-fold increased congenital hypothyroidism risk in GG homozygotes. The same variant that lowers TSH in healthy adults appears to increase vulnerability to thyroid dysgenesis or hypoplasia during fetal development.

The Evidence

The most comprehensive evidence for this variant's effects comes from a Danish twin study of 1,241 healthy adults⁸⁸ a Danish twin study of 1,241 healthy adults
Peeters et al. Eur J Endocrinol 2007, which found genotype frequencies of Asp/Asp 84.9%, Asp/Glu 14.5%, and Glu/Glu 0.6%. Carriers of the Glu727 allele (CG or GG genotypes) had significantly lower serum TSH levels⁹⁹ significantly lower serum TSH levels
1.60 ± 0.84 vs 1.78 ± 0.93 mU/L, P=0.04 compared to non-carriers, with regression analysis confirming the association (P=0.007). However, the polymorphism accounted for only 0.91% of total phenotypic variance in TSH levels and showed no association with thyroid size, thyroid hormones, or thyroid antibody levels¹⁰¹⁰ no association with thyroid size, thyroid hormones, or thyroid antibody levels
Suggesting specific effect on TSH regulation, indicating its influence is limited to the TSH feedback setpoint rather than broader thyroid function.

In the context of thyroid disease, a meta-analysis combining 1,044 congenital hypothyroidism cases and 1,649 controls¹¹¹¹ a meta-analysis combining 1,044 congenital hypothyroidism cases and 1,649 controls
Kollati et al. 3 Biotech 2020 found that the G-allele increased congenital hypothyroidism risk by 45%¹²¹² increased congenital hypothyroidism risk by 45%
OR: 1.45, 95% CI 1.20-1.76 in fixed-effect models, with the GG genotype showing a 2.3-fold increased risk¹³¹³ 2.3-fold increased risk
OR: 2.30, 95% CI 1.32-3.99. This association was consistent across seven published studies and is thought to reflect the variant's impact on cAMP-mediated thyroid development during gestation. Interestingly, early research into autoimmune thyroid diseases like Graves' disease initially examined rs1991517 but later excluded it¹⁴¹⁴ initially examined rs1991517 but later excluded it
Frequently present in healthy individuals, suggesting it is not a major driver of autoimmune thyroid pathology.

Beyond thyroid-specific effects, the variant has been linked to metabolic parameters. In a study of 349 nondiabetic elderly men¹⁵¹⁵ a study of 349 nondiabetic elderly men
Peeters et al. Clin Endocrinol 2007, carriers of the Glu727 allele showed significantly elevated markers of insulin resistance¹⁶¹⁶ significantly elevated markers of insulin resistance
Glucose (P=0.01), insulin (P=0.001), HbA1c (P=0.002), HOMA-IR (P=0.001), and leptin (P=0.008). The authors suggest this reflects direct TSH receptor activity in adipose tissue, where TSHR is expressed and may influence glucose metabolism independent of circulating thyroid hormone levels. Additionally, the Rotterdam Study found Glu727 carriers had 2.3% higher femoral neck bone mineral density¹⁷¹⁷ the Rotterdam Study found Glu727 carriers had 2.3% higher femoral neck bone mineral density
P=0.03, potentially mediated by the lower TSH levels, since TSH receptors are also expressed in bone.

Practical Implications

If you carry the Glu727 variant (CG or GG genotype), your baseline TSH levels may run lower than population averages while still being entirely normal for you. This has implications for thyroid function testing: what appears to be "low-normal" TSH (e.g., 0.8-1.5 mU/L) may be your optimal setpoint rather than a sign of subclinical hyperthyroidism. TSH levels vary significantly based on genetic factors¹⁸¹⁸ TSH levels vary significantly based on genetic factors
TSHR polymorphisms account for measurable variance in TSH setpoints, so individualized reference ranges are more meaningful than population-wide cutoffs.

For parents or prospective parents carrying the G-allele, awareness of the modest increase in congenital hypothyroidism risk may inform discussions about newborn screening. Standard newborn screening programs measure TSH at 4-5 days of life¹⁹¹⁹ Standard newborn screening programs measure TSH at 4-5 days of life
99% coverage in developed countries, so any thyroid dysgenesis would be caught early, but knowing the genetic predisposition reinforces the importance of ensuring screening is completed.

The metabolic associations—particularly insulin resistance in Glu727 carriers—suggest that maintaining metabolic health through lifestyle measures may be especially important. While the variant's effect size is modest, it adds to the cumulative genetic and environmental factors influencing glucose metabolism. Similarly, the higher bone mineral density in carriers is a protective factor, potentially offsetting other genetic or lifestyle-related osteoporosis risks.

Optimal thyroid function depends on adequate selenium and iodine intake²⁰²⁰ selenium and iodine intake
Selenium for deiodinase function, iodine as structural component of T4/T3. While the TSHR variant affects receptor sensitivity rather than thyroid hormone synthesis directly, ensuring micronutrient sufficiency supports overall thyroid axis function. Zinc also plays a role in TSH regulation²¹²¹ Zinc also plays a role in TSH regulation
Influences TSH release from pituitary and T4-to-T3 conversion, making it a relevant consideration for comprehensive thyroid support.

Interactions

The TSHR Asp727Glu variant interacts with polymorphisms in the DIO2 gene (particularly rs225014, Thr92Ala), which controls conversion of T4 to active T3 in peripheral tissues. A study of congenital hypothyroidism patients found concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism²²²² A study of congenital hypothyroidism patients found concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism
Combined effects are additive. Specifically, TSHR variants affect the production of T4 from the thyroid gland, while DIO2 variants affect local T3 production from circulating T4. Individuals with both TSHR Glu727 (lower TSH drive) and DIO2 Ala92 (reduced T4-to-T3 conversion) may experience a "double hit" scenario where both hormone production and peripheral activation are compromised, potentially requiring more careful thyroid hormone replacement strategies if hypothyroidism develops.

The variant's effect on TSH levels also influences the broader hypothalamic-pituitary-thyroid (HPT) and hypothalamic-pituitary-adrenal (HPA) axis interaction. Stress and cortisol affect thyroid hormone secretion²³²³ Stress and cortisol affect thyroid hormone secretion
CRH and cortisol can suppress TSH and alter T4-to-T3 conversion, and individuals with genetically lower baseline TSH (like Glu727 carriers) may be more vulnerable to stress-induced thyroid dysfunction. Chronic stress leading to elevated cortisol can further suppress already-low TSH levels, potentially pushing carriers toward subclinical hypothyroidism.

The sleep-thyroid connection is another relevant interaction. TSH follows a circadian rhythm with natural elevation during early sleep²⁴²⁴ TSH follows a circadian rhythm with natural elevation during early sleep
Melatonin production signals nighttime thyroid adjustments, and disruption of sleep patterns (shift work, insomnia, sleep apnea) can dysregulate TSH secretion. Glu727 carriers with altered TSH setpoints may be particularly sensitive to circadian disruption, making consistent sleep-wake cycles especially important for maintaining stable thyroid function.

The VEGFA gene encodes vascular endothelial growth factor A¹¹ vascular endothelial growth factor A
The master regulator of angiogenesis (new blood vessel formation), critical for oxygen delivery to tissues, the master regulator of angiogenesis — the formation of new blood vessels. This promoter variant, located at position -634 in the gene's regulatory region, directly affects how much VEGF-A your cells produce. The C allele increases VEGF-A expression, leading to higher circulating levels and greater angiogenic potential. The G allele results in lower baseline VEGF production.

This SNP is one of only three genetic variants with replicated findings²² replicated findings
Among 99 unique polymorphisms studied in football players, only ACTN3 R577X, ACAN rs1516797, and VEGFA rs2010963 showed consistent associations across independent cohorts across independent cohorts of professional football players — making it among the most robust findings in sports genetics. But its implications extend far beyond athletics: VEGF levels influence wound healing, cardiovascular health, exercise adaptation, and soft tissue injury susceptibility.

The Mechanism

The -634G>C polymorphism sits in the 5′-untranslated region of the VEGFA gene, a regulatory region that controls gene expression³³ gene expression
Transcription rates determine how much protein gets made from a gene. The C allele enhances promoter activity, resulting in higher VEGFA mRNA levels and increased protein production. Functional studies⁴⁴ Functional studies
Vailati et al. 2012 — analysis of 53 human retinal samples show that C-allele carriers (CC or CG genotypes) have significantly higher VEGFA gene expression than GG individuals (5.15 and 3.72 arbitrary units vs 2.62, P=0.045).

VEGF-A is the central angiogenic factor in skeletal muscle. During exercise, muscle contraction triggers VEGF release into the muscle interstitium⁵⁵ muscle interstitium
The fluid-filled space between muscle fibers and capillaries, where it binds to VEGF receptors on capillary endothelial cells. This stimulates two forms of capillary growth: sprouting angiogenesis⁶⁶ sprouting angiogenesis
New capillaries bud from existing vessels through endothelial cell proliferation and basement membrane remodeling (driven by VEGF signaling) and longitudinal splitting⁷⁷ longitudinal splitting
A capillary lumen splits into two parallel vessels through mechanical stretching of endothelial cells (driven by shear stress and nitric oxide). Higher baseline VEGF production in C-allele carriers means a stronger angiogenic response to training stimuli.

But VEGF also upregulates matrix metalloproteinases⁸⁸ matrix metalloproteinases
MMPs — enzymes that degrade extracellular matrix proteins including collagen (MMPs), which are necessary for capillary growth but also weaken the extracellular matrix (ECM). Since more than 80% of muscle force⁹⁹ more than 80% of muscle force
Force transmission research shows lateral force transfer to ECM is critical for strength is transmitted laterally to the ECM rather than along the muscle fiber, excessive MMP activity may impair force transmission. This explains why GG individuals — with lower VEGF and thus lower MMP activity — show superior strength gains from resistance training.

The Evidence

The most rigorous evidence comes from a within-subject crossover study¹⁰¹⁰ within-subject crossover study
Pickering et al. 2023 — 30 healthy men completed both resistance and endurance training in random order where 30 healthy men completed both resistance training (4 weeks of knee extensions at 80% 1-RM) and endurance training (4 weeks of cycling at 70-90% max heart rate), separated by a 3-week washout. VEGFA rs2010963 GG homozygotes increased maximum strength by +20.9% after resistance training but only +8.4% in VO₂peak after endurance training (P=0.005). In contrast, C-allele carriers gained only +12.2% strength — significantly less than GG individuals (P=0.04) — though their endurance improvements were comparable.

The authors propose that lower VEGF in GG individuals preserves ECM integrity during resistance training, allowing more effective lateral force transmission and greater hypertrophy. C-allele carriers' higher VEGF drives angiogenesis but also MMP-mediated ECM degradation, blunting their strength response.

For injury risk, the evidence is equally compelling. A meta-analysis¹¹¹¹ meta-analysis
Zhang et al. 2024 — systematic review of 4 studies with 1,061 cases and 986 controls of tendon and ligament injuries found that in European populations, the CC genotype conferred OR 1.40 (95% CI 1.00-1.94, P=0.049) for injury risk compared to GG. The C allele itself showed OR 1.15 (95% CI 1.00-1.32, P=0.045), with the G allele demonstrating protective effects. Specifically, rs2010963 CC¹²¹² rs2010963 CC
Systematic review of genetic predisposition to injury in football homozygotes had greater risk of ACL and ligament/tendon injury than G-allele carriers, replicated across two independent football cohorts.

The mechanism is likely tied to VEGF's role in tissue healing¹³¹³ tissue healing
VEGF is highly expressed 2-3 weeks post-ACL surgery and critical for graft remodeling. While adequate angiogenesis is necessary for tendon repair, excessive VEGF upregulates MMPs that degrade collagen, weakening connective tissue structure. CC individuals' chronically higher VEGF may predispose to tendon/ligament fragility under load.

Training Adaptations

The GG genotype confers a clear advantage for resistance training. The +20.9% strength gain in GG individuals versus +12.2% in C-allele carriers represents a 71% greater adaptation to the same training stimulus. This is among the largest effect sizes for any single SNP in exercise genetics.

For endurance training, the picture is more nuanced. C-allele carriers have higher circulating VEGF and greater angiogenic potential, which theoretically should enhance capillary density and oxygen delivery. Some studies report better aerobic capacity¹⁴¹⁴ better aerobic capacity
C allele associated with higher VO₂max values in some cohorts in C-allele carriers. However, the crossover study found no significant difference in VO₂peak gains between genotypes (+8-9% for both). This may reflect that angiogenesis, while important, is just one of many adaptations to endurance training (mitochondrial biogenesis, fiber-type shifts, etc.).

Injury Prevention

For C-allele carriers — particularly CC homozygotes — soft tissue injury risk is elevated. This is especially relevant for athletes in high-stress sports (football, basketball, skiing) where ACL and tendon injuries are common. The OR 1.40 for CC versus GG translates to roughly 40% higher odds of injury per exposure event, though absolute risk depends on sport, training load, and biomechanics.

Interactions

VEGFA rs2010963 is part of a functional haplotype with two other promoter SNPs: rs699947¹⁵¹⁵ rs699947
-2578C/A polymorphism in VEGFA promoter (-2578C/A) and rs1570360¹⁶¹⁶ rs1570360
-1154G/A polymorphism in VEGFA promoter (-1154G/A). The A-G-G haplotype (rs699947-rs1570360-rs2010963) has been associated with increased risk of chronic Achilles tendon injury. Individuals carrying multiple high-VEGF alleles across these SNPs may have compounded angiogenic drive and correspondingly greater MMP activity.

The interplay with nitric oxide¹⁷¹⁷ nitric oxide
NO is produced by endothelial NOS in response to shear stress and by neuronal NOS during muscle contraction (NO) is also critical. NO and VEGF work synergistically: VEGF upregulates endothelial NOS (eNOS), and NO in turn enhances VEGF receptor sensitivity. Genetic variants affecting NO production (e.g., NOS3¹⁸¹⁸ NOS3
Endothelial nitric oxide synthase gene polymorphisms polymorphisms) may modulate the phenotypic effects of VEGFA rs2010963.

The FADS2 gene encodes delta-6 desaturase¹¹ delta-6 desaturase
delta-6 desaturase (D6D) is the rate-limiting enzyme in the conversion of linoleic acid (LA) and alpha-linolenic acid (ALA) to their longer-chain products, the gateway enzyme controlling how your body converts essential fatty acids from food into the biologically active long-chain polyunsaturated fatty acids (LC-PUFAs) — including arachidonic acid (AA), EPA, and DHA. rs2072114 is an intronic SNP in the first intron of FADS2, sitting within the broader FADS1/FADS2 haplotype block²² FADS1/FADS2 haplotype block
A haplotype block is a stretch of DNA where nearby variants tend to be inherited together as a unit on chromosome 11q12-13. Though non-coding, it serves as a reliable tag for functional variation in this cluster that modulates desaturase enzyme output.

The Mechanism

Delta-6 desaturase performs the first and most critical step in converting short-chain dietary omega-6 and omega-3 fatty acids into their longer, more bioactive derivatives. For omega-6s: LA → GLA → DGLA → AA. For omega-3s: ALA → SDA → EPA → DHA. The G allele of rs2072114 is associated with altered n-6 desaturase activity — the direction of effect (increased or decreased) is population- and sex-specific, reflecting interactions between genetic background and hormonal environment. In populations studied, the net result tends to shift fatty acid profiles toward lower arachidonic acid production relative to linoleic acid precursor, and may reduce delta-5 and delta-6 desaturase efficiency for certain conversions in specific subgroups.

Because rs2072114 lies within a strong linkage disequilibrium block, its observed associations partly reflect correlated effects of neighboring functional FADS2 variants (rs174575, rs174576, rs174602) rather than a direct effect of the intronic position itself.

The Evidence

A cross-sectional study by Abdelmagid et al.³³ cross-sectional study by Abdelmagid et al.
Abdelmagid et al. Ethnicity, sex, FADS genetic variation, and hormonal contraceptive use influence delta-5- and delta-6-desaturase indices and plasma DHA concentration in young Canadian adults. Nutr Metab, 2015 of 787 Caucasian and East Asian young adults found that rs2072114 was significantly associated with aggregate n-6 desaturase indices, with effects that were ethnicity- and sex-specific. East Asian females showed the most pronounced associations after multiple-testing correction.

A Taiwanese clinical study by Huang et al.⁴⁴ Taiwanese clinical study by Huang et al.
Huang et al. Interaction among dietary n-3 and n-6 PUFA intake, FADS2 genetic variants, and LDL-C in type 2 diabetes patients. J Diabetes Investig, 2023 in 816 type 2 diabetes patients found that the G allele of rs2072114 showed a significant gene-diet interaction (P = 0.016): among individuals with a low alpha-linolenic acid/linoleic acid ratio in their diet, G allele carriers had lower LDL-C concentrations. This suggests the metabolic effect of this variant is diet-sensitive and most pronounced when omega-3 dietary intake is relatively low.

Broader evidence for the FADS1/FADS2 locus⁵⁵ FADS1/FADS2 locus
Tanaka et al. GWAS of plasma PUFA in InCHIANTI study. PLoS Genet, 2009 confirms this genomic region is the dominant genetic determinant of circulating PUFA levels — the lead SNP rs174537 explains 18.6% of variance in arachidonic acid concentrations. rs2072114 tags this same haplotype block.

Practical Actions

The G allele's effect on fatty acid desaturation is context-dependent. The most robust intervention is ensuring a dietary n-3/n-6 ratio that limits the functional impact of reduced conversion efficiency. G allele carriers benefit from increasing preformed EPA and DHA from marine or algae-based sources, rather than relying solely on ALA conversion from plant oils. Monitoring lipid panels — particularly LDL-C in the context of dietary fatty acid composition — gives personalized feedback on whether the genetic effect is clinically active.

Interactions

rs2072114 sits within the same haplotype block as rs174547 (FADS1) and rs174575, rs174576, rs174602 (FADS2). Carriers of multiple variant alleles across this cluster may have additive reductions in both delta-5 and delta-6 desaturase activity, amplifying the need for preformed LC-PUFAs. The ELOVL2 gene (rs953413, chromosome 6) is a pathway partner — it handles the elongation step after FADS2 has performed initial desaturation, so combined variation across FADS2 and ELOVL2 can further reduce DHA synthesis efficiency.